Why the study?
What circulating biomarkers can be used for the noninvasive diagnosis and assessment of myocardial fibrosis?
What circulating biomarkers can be used for the noninvasive diagnosis and assessment of myocardial fibrosis?
Circulating biomarkers offer a noninvasive alternative to tissue biopsy for the early detection and assessment of myocardial fibrosis.
Supports noninvasive fibrosis assessment in research; leaves open clinical adoption pending prospective validation.
Myocardial fibrosis is observed in many cardiovascular diseases including hypertension, heart failure and cardiomyopathy. Myocardial fibrosis has been proved to be reversible and treatable only under timely intervention, which makes early detection and assessment of fibrosis crucial. Aside from tissue biopsy as the gold standard for the diagnosis of myocardial fibrosis, circulating biomarkers have been adopted as noninvasive assessment of this lesion. Dysregulated collagen deposition is thought to be the major cause of myocardial fibrosis. Collagens, procollagens, TGF-β, TIMP, galectin-3, and microRNAs are thought to be indicators of myocardial fibrosis. In this review, we summarize the molecules that are frequently used as biomarkers in diagnosis of cardiac fibrosis. Mechanisms of fibrosis that they take part in are also introduced.
No takes yet. Share an insight, caveat, or question.
An et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: